Release
📈 Stocks
Eli Lilly Reports Positive Phase 3 Retatrutide Data for Knee Osteoarthritis
(just now)
Eli Lilly shares see potential upside as Phase 3 trials for retatrutide show substantial efficacy in treating knee osteoarthritis and obesity, with…